Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that inhibits human VEGF.[14] Ranibizumab is approved for intravitreal injection for choroidal neovascularization and bevacizumab is approved for intravenous use for metastatic colorectal cancer. This evidence concerns the gene VEGFA and metastatic colorectal cancer.